Does Michigan Medicaid Cover Wegovy or Zepbound? BMI 40 and the Five-Drug Rule

Only for a narrow group. As of November 2026 Michigan Medicaid will approve Wegovy or Zepbound for weight loss only at a BMI of 40 or more, after trial and failure of five types of older drugs, and only as a way to avoid bariatric surgery.^[2] Other uses face a far lower bar: Wegovy for heart disease or the liver disease MASH and Zepbound for sleep apnea each start at a BMI of 27.^[2]

Why did Michigan Medicaid restrict GLP-1s for weight loss?

Because the legislature told it to. Section 1880 of the 2025 budget act directed the health department to limit anti-obesity GLP-1s to people classified as morbidly obese, to make coverage depend on documented failure of other suitable interventions, and to treat the drug only as a way around costlier weight-loss surgery.^[1] The new criteria applied from January 1, 2026, to every Michigan Medicaid member, whichever plan they use.^[5] The budget for the year that began October 1, 2026, repeats the limit, now worded as class III obesity, but only if the department does not take part in a federal pharmaceutical savings program that year. The act does not name a program.^[13] The criteria revised November 1, 2026, still apply the limit, so watch for a change if Michigan joins one.^[2] States may limit these drugs under federal law, and Michigan chose a middle path: unlike Illinois and Arkansas, which do not cover weight loss alone, it kept a route, but one few people can reach.^[8]

What does it take to get Wegovy or Zepbound approved for weight loss?

1. Five types of older drugs first. Allergy, contraindication, side effects, or trial and failure must cover benzphetamine, diethylpropion, an orlistat product, phendimetrazine and a phentermine product.^[2]
2. A BMI that counts as morbid obesity. The criteria give a baseline BMI of 40 or more as the example for adults. For ages 12 to 17, the prescriber attests the child is classified that way on CDC growth charts.^[2]
3. Two attestations from the law. The prescriber confirms that other suitable interventions failed and that the drug is a last step before an operation the state wants to avoid paying for.^[1][2]
4. The right age for the product. Age 18 for Zepbound, Wegovy tablets and Wegovy HD; age 12 for the Wegovy injection, Saxenda, liraglutide and Foundayo.^[2]
5. Clinical screens. No second weight-loss drug, no DPP-4 inhibitor, other causes of obesity ruled out or treated, no pregnancy, lactation, medullary thyroid cancer or MEN 2, and a diet and activity plan suited to the person’s ability.^[2]

The first step is the part a BMI headline hides. Approval runs six months, and renewal requires keeping off at least 5% of starting weight, or for children, holding or improving BMI percentile.^[2] So getting through can take many months of other medication before a GLP-1 request is even complete. Each older drug carries its own prior authorization, starting at a BMI of 30, or 27 with a risk factor such as hypertension.^[4] Our comparison of phentermine and a GLP-1 sets out how much less those drugs tend to do.

The surgery language is also unusual, because the criteria ask for an attestation, not a surgical referral or evaluation. The state does not spell out what would satisfy it. Our page on surgery versus GLP-1 drugs explains how far apart the two are on weight, which is useful context when a request has to weigh one against the other.

Does Michigan Medicaid cover Wegovy for heart disease?

Yes, with prior authorization, and without the five-drug step. Michigan has separate classes for each non-weight use, with their own forms and tests.^[3] The table shows how different they are from the weight-loss route.

Michigan’s heart route is more open than some others: it has no age-45 line, matching a label written for adults.^[2][9] Compare Texas, which starts at 45. The criteria file we read prints the heart renewal’s first line, ending in “AND,” and then no second condition, so ask whether a weight test applies.^[2]

Does Michigan Medicaid cover Zepbound for sleep apnea?

Yes. Zepbound is the preferred drug in its own sleep apnea class.^[3] The request needs a documented moderate to severe diagnosis and a BMI of 27 or more, and the criteria we read list no specific apnea-hypopnea number or trial of CPAP.^[2] That BMI floor is below the label’s use, which is for adults with obesity, so a prescriber should be ready to explain a lower-BMI request.^[10] Vials are not covered by Medicaid, according to the state’s change log, while the KwikPen is on the list.^[2] See Zepbound for sleep apnea for the evidence behind the use.

Does Michigan Medicaid cover Wegovy for MASH?

Yes, for adults with noncirrhotic MASH and moderate to advanced fibrosis, consistent with stages F2 to F3, and a BMI of 27 or more.^[2] Michigan’s criteria rely on the prescriber’s attestation and do not name a required test or time window, though renewal asks for 5% of starting weight kept off.^[2] Someone who loses less than that should raise it with the prescriber before renewal. Our guide to GLP-1s and fatty liver covers the trial.

What happens to people who were already taking Wegovy or Zepbound?

Existing approvals ran to the end of the current authorization, and renewals then met the new rules.^[5] The criteria include a transition step for the first renewal: the prescriber confirms the person met the morbid obesity label at the start, that other interventions had failed, and that surgery avoidance was the purpose, and adds the 5% weight record.^[2] A patient whose starting BMI fell short has no route for weight loss, and should check whether a heart, liver or sleep use applies.

Does Michigan Medicaid cover Ozempic for diabetes?

Yes. The budget change did not touch diabetes coverage.^[5] The criteria ask for a type 2 diabetes diagnosis and that other GLP-1s and DPP-4 inhibitors are stopped, with approval lasting a year.^[2] The state’s change log shows Ozempic and Mounjaro moved to preferred status and Ozempic tablets added as non-preferred, so check the current list.^[2] A non-preferred product generally needs a trial of a preferred one in the same group first.^[2]

How do you appeal a denial in Michigan?

• Plan appeal. Federal rules give you 60 calendar days from the notice.^[7]
• State fair hearing. One Michigan plan tells members they have 120 calendar days from the mailed appeal denial.^[6]
• External review. The same plan describes a request to the state insurance regulator within 127 calendar days.^[6]

Appeals work best on the record: a missed trial that was in fact tried, or a BMI that was measured at baseline. Our guide to prior authorization and appeals shows what to include. A prescriber should not record a diagnosis you do not have.

What are the options if you don't qualify?

The older drugs are the covered path, and the department also suggests diabetes prevention programs.^[2][3] Cash is the other route, and Lilly’s savings card excludes government programs.^[11] Prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose up to $449 at higher doses for Lilly’s Zepbound KwikPen or vial.^[11][12] Check each offer’s terms for Medicaid members. The guide to the lowest GLP-1 prices without insurance compares them.